ClinicalTrials.gg
CompletedNCT02196506Updated Aug 21, 2018Results posted

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

A Phase 3 interventional study of Placebo + ADT and Brexpiprazole +ADT in Depressive Disorder, Depression and Depressive Disorder, Major, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 47 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-08-21.

Primary conditionDepressive Disorder, MajorRegistry: Depressive DisorderReclassifiedWhy we changed it
Registry
Depressive Disorder — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depressive Disorder, Major
Why
  1. The study's listed conditions name Depressive Disorder, Major, a narrower term within Depressive Disorder.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
837
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
7th of 24
837 · median 189
Started
2014
with 1 other
Phase 3
16 of 24
none open now
Registered
15th of 24
by date
Lead sponsor
15 of 24
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 7th largest by enrollment, is one of 2 that started in 2014, is one of 16 in phase 3, and was the 15th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to assess the tolerability, safety, and efficacy of brexpiprazole (2.0 mg/day) as adjunctive therapy in adult subjects with a diagnosis of MDD with and without anxious distress

Read the detailed description

The introduction of atypical antipsychotics has created a renewed interest in adjunctive therapy for MDD, particularly for treatment-resistant MDD. Several atypical antipsychotics have been shown to enhance the response to ADT. This is a phase 3, multicenter, randomized, double-blind, placebo-controlled, fixed-dose trial designed to assess the safety and efficacy of brexpiprazole (2.0 mg/day) as adjunctive therapy to an assigned open-label ADT in depressed subjects with and without anxious distress.

03

Conditions studied

  • Depressive Disorder
  • Depression
  • Depressive Disorder, Major
  • Mood Disorders
  • Mental Disorders

Keywords

  • OPC-34712
  • brexpiprazole
  • Major Depressive Disorder
  • Adjunctive Treatment
  • Anxious Distress
04

In context

Depressive Disorder, Major Reclassified

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

This study's enrollment of 837 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.

Browse Depressive Disorder, Major studies →

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.

Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.

Compared within Depressive Disorder, Major, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Depressive Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female subjects between 18-65 years of age, with diagnosis of major depressive disorder with or without anxious distress
  • Current depressive episode must be at least 8 weeks in duration

Exclusion criteria

Exclusion Criteria:

  • Subjects with a history of Neuroleptic Malignant Syndrome or Serotonin Syndrome
  • Subjects who report an inadequate response to more than 3 antidepressant treatments in the current episode
  • Subjects with a current Axis I diagnosis of: Delirium, dementia, amnestic or other cognitive disorder, Schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder
06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
837 participants (actual)

Study arms

  • Experimental
    Brexpiprazole + ADT

    Brexpiprazole + ADT

    Drug: Brexpiprazole +ADT

  • Placebo comparator
    Placebo + ADT

    Placebo + ADT

    Drug: Placebo + ADT

Interventions

  • DrugPlacebo + ADT

    Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)

  • DrugBrexpiprazole +ADT

    Drug pages: Brexpiprazole · Antiandrogens

    Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)

07

What researchers measure

Primary outcomes

  1. Change in the Montgomery-Asberg Depression

    To assess the change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score from Baseline (End of Phase A \[Week 8\]) to Week 14. The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). The MADRS consisted of 10 items each with 7 defined grades of severity. The rater decided whether the rating lied on predefined scale steps (0, 2, 4, 6) or between them (1, 3, 5). The 10 items were apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score was 60; 0, no symptom; 60, severely affected.

    Time frame: From baseline (end of Phase A [Week 8]) to week 14

Secondary outcomes

  1. Change in the Sheehan Disability Scale (SDS) From Baseline to End of Treatment

    To assess the change in the Sheehan Disability Scale (SDS) Score (the mean of 3 individual item scores) from Baseline (End of Phase A \[Week 8\]) to Week 14 (End of Phase B). SDS was a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life, and family life/home responsibility. Each item was scored using a scale of 0 to 10 (a higher score indicates symptoms have disrupted work, social life, and family life/home responsibility extremely). The maximum total score was 30; 0 = not at all, to 30 = extremely.

    Time frame: From baseline (end of Phase A [Week 8]) to week 14

  2. Change From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulation With <25% Improvement From Baseline of Phase A to End of Phase A in MADRS Total Score

    To assess the change from end of Phase A (Week 8 visit) to end of Phase B (Week 14 visit) in MADRS Total Score for the subpopulation with \< 25% improvement from baseline of Phase A (Week 0) to end of Phase A (Week 8) in MADRS Total Score. The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). The MADRS consisted of 10 items each with 7 defined grades of severity. The 10 items were apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score was 60; 0, no symptom; 60, severely affected.

    Time frame: From baseline (end of Phase A [Week 8]) to week 14

  3. Change From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulations With Anxious Distress as Specified in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).

    To assess the change from end of Phase A (Week 8) to end of Phase B (Week 14) in MADRS Total Score for the subpopulations with anxious distress as specified in DSM-V. The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). The MADRS consisted of 10 items each with 7 defined grades of severity. The 10 items were apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score was 60; 0, no symptom; 60, severely affected.

    Time frame: From baseline (end of Phase A [Week 8]) to week 14

08

Results

Posted Aug 21, 2018

Participant flow

This trial was conducted in 837 participants at 51 trial sites in the following 5 countries:Germany,Hungary,Poland,Slovakia,andUnited States (US).A total of 1144 participants with major depressive disorder were screened for the trial, 837 enrolled into Phase A,394 were randomized into Phase B and 322 continued treatment with placebo+ADT in Phase A+

Phase A
Participant flow — Phase A
MilestonePhase A: All ADT (Antidepressant Therapy)Phase B: Brexpiprazole + ADTPhase B: Placebo + ADTPhase A +: ALL ADT
Started837000
Completed716000
Not completed121000
Withdrew: Participant met withdrawal criteria34000
Withdrew: Withdrawal by subject34000
Withdrew: Adverse event22000
Withdrew: Lost to follow-up9000
Withdrew: Protocol deviation12000
Withdrew: Participant withdrawn by investigator10000
Phase B
Participant flow — Phase B
MilestonePhase A: All ADT (Antidepressant Therapy)Phase B: Brexpiprazole + ADTPhase B: Placebo + ADTPhase A +: ALL ADT
Started01922020
Completed01771960
Not completed01560
Withdrew: Participant met withdrawal criteria0010
Withdrew: Lack of efficacy0120
Withdrew: Withdrawal by participant0810
Withdrew: Adverse event0410
Withdrew: Lost to follow-up0210
Phase A+
Participant flow — Phase A+
MilestonePhase A: All ADT (Antidepressant Therapy)Phase B: Brexpiprazole + ADTPhase B: Placebo + ADTPhase A +: ALL ADT
Started000322
Completed000308
Not completed00014
Withdrew: Participant met withdrawal criteria0001
Withdrew: Withdrawal by participant0005
Withdrew: Adverse event0001
Withdrew: Lost to follow-up0006
Withdrew: Participant withdrawn by investigator0001

Outcome measures

PrimaryChange in the Montgomery-Asberg Depression

To assess the change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score from Baseline (End of Phase A \[Week 8\]) to Week 14. The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). The MADRS consisted of 10 items each with 7 defined grades of severity. The rater decided whether the rating lied on predefined scale steps (0, 2, 4, 6) or between them (1, 3, 5). The 10 items were apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score was 60; 0, no symptom; 60, severely affected.

Time frame:
From baseline (end of Phase A [Week 8]) to week 14
Reported as:
Least squares mean · Units on a scale
Change in the Montgomery-Asberg Depression
Units on a scaleBrexpiprazole + ADTPlacebo + ADT
Change in the Montgomery-Asberg Depression-10.4 ± 0.63-8.07 ± 0.61
Statistical analysis
  • Brexpiprazole + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0074 · Mean difference (final values): -2.30 · 95% CI -3.97 to -0.62
SecondaryChange in the Sheehan Disability Scale (SDS) From Baseline to End of Treatment

To assess the change in the Sheehan Disability Scale (SDS) Score (the mean of 3 individual item scores) from Baseline (End of Phase A \[Week 8\]) to Week 14 (End of Phase B). SDS was a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life, and family life/home responsibility. Each item was scored using a scale of 0 to 10 (a higher score indicates symptoms have disrupted work, social life, and family life/home responsibility extremely). The maximum total score was 30; 0 = not at all, to 30 = extremely.

Time frame:
From baseline (end of Phase A [Week 8]) to week 14
Reported as:
Least squares mean · Units on a scale
Change in the Sheehan Disability Scale (SDS) From Baseline to End of Treatment
Units on a scaleBrexpiprazole + ADTPlacebo + ADT
Change in the Sheehan Disability Scale (SDS) From Baseline to End of Treatment-1.63 ± 0.18-1.41 ± 0.17
Statistical analysis
  • Brexpiprazole + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.3331 · Mean difference (final values): -0.22 · 95% CI -0.66 to 0.23
SecondaryChange From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulation With <25% Improvement From Baseline of Phase A to End of Phase A in MADRS Total Score

To assess the change from end of Phase A (Week 8 visit) to end of Phase B (Week 14 visit) in MADRS Total Score for the subpopulation with \< 25% improvement from baseline of Phase A (Week 0) to end of Phase A (Week 8) in MADRS Total Score. The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). The MADRS consisted of 10 items each with 7 defined grades of severity. The 10 items were apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score was 60; 0, no symptom; 60, severely affected.

Time frame:
From baseline (end of Phase A [Week 8]) to week 14
Reported as:
Least squares mean · Units on a scale
Change From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulation With <25% Improvement From Baseline of Phase A to End of Phase A in MADRS Total Score
Units on a scaleBrexpiprazole + ADTPlacebo + ADT
Change From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulation With <25% Improvement From Baseline of Phase A to End of Phase A in MADRS Total Score-11.1 ± 0.71-8.87 ± 0.71
Statistical analysis
  • Brexpiprazole + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0263 · Mean difference (final values): -2.25 · 95% CI -4.23 to -0.27
SecondaryChange From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulations With Anxious Distress as Specified in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).

To assess the change from end of Phase A (Week 8) to end of Phase B (Week 14) in MADRS Total Score for the subpopulations with anxious distress as specified in DSM-V. The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). The MADRS consisted of 10 items each with 7 defined grades of severity. The 10 items were apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score was 60; 0, no symptom; 60, severely affected.

Time frame:
From baseline (end of Phase A [Week 8]) to week 14
Reported as:
Least squares mean · Units on a scale
Change From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulations With Anxious Distress as Specified in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
Units on a scaleBrexpiprazole + ADTPlacebo + ADT
Change From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulations With Anxious Distress as Specified in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).-11.8 ± 0.81-8.87 ± 0.81
Statistical analysis
  • Brexpiprazole + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0099 · Mean difference (final values): -2.98 · 95% CI -5.24 to -0.72

Adverse events

Collected over Participants were assessed for the occurrence of adverse events (AEs) once the participant signed informed consent form through completion of the trial; up to 14-weeks after the participant entered the trial and actively monitored up to 30 (+2) days after their last dose of investigational medicinal product (this could be up to 22 weeks depending on duration of trial participation).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole + ADT0/192 (0%)1/192 (0.5%)49/192 (25.5%)
Placebo + ADT0/202 (0%)0/202 (0%)35/202 (17.3%)
Most frequent serious events
Most frequent serious events
EventBrexpiprazole + ADTPlacebo + ADT
VertigoEar and labyrinth disorders1/1920/202
Most frequent other events
Most frequent other events
EventBrexpiprazole + ADTPlacebo + ADT
AkathisiaNervous system disorders16/19210/202
RestlessnessPsychiatric disorders16/1924/202
HeadacheNervous system disorders7/19215/202
Upper Respiratory Tract InfectionInfections and infestations10/19210/202
Weight IncreasedInvestigations10/1921/202

Baseline characteristics

Baseline measures are based on the participants from the Double-blind Randomization Phase

Age, Continuous
Age, Continuous(years)Brexpiprazole + ADTPlacebo + ADTTotal
Mean43.0 ± 12.742.7 ± 12.542.9 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole + ADTPlacebo + ADTTotal
Female147144291
Male4558103
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brexpiprazole + ADTPlacebo + ADTTotal
Hispanic or Latino11920
Not Hispanic or Latino181192373
Unknown011
Region of Enrollment
Region of Enrollment(participants)Brexpiprazole + ADTPlacebo + ADTTotal
Hungary161632
United States100106206
Poland262652
Slovakia232548
Germany272956
09

Study locations

47 sites
  • Birmingham, Alabama, United States
  • Beverly Hills, California, United States
  • Denver, Colorado, United States
  • Hialeah, Florida, United States
  • Orlando, Florida, United States
  • Alpharetta, Georgia, United States
  • Smyrna, Georgia, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Rochester Hills, Michigan, United States
  • Cherry Hill, New Jersey, United States
  • Jamaica, New York, United States
  • New York, New York, United States
  • Staten Island, New York, United States
  • Raleigh, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Edmond, Oklahoma, United States
  • Portland, Oregon, United States
  • Salem, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Lincoln, Rhode Island, United States
  • Columbia, South Carolina, United States
  • Memphis, Tennessee, United States
  • Wichita Falls, Texas, United States
  • Murray, Utah, United States
  • Woodstock, Vermont, United States
  • Charlottesville, Virginia, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
  • Spokane, Washington, United States
  • Achim, Germany
  • Berlin, Germany
  • Dusseldorf, Germany
  • Frankfurt, Germany
  • Freiburg, Germany
  • Oranienburg, Germany
  • Stralsund, Germany
  • Wurzburg, Germany
  • Budapest, Hungary
  • Gyor, Hungary
  • Gdansk, Poland
  • Lubin, Poland
  • Sosnowiec, Poland
  • Warszawa, Poland
  • Bratislava, Slovakia
  • Kosice-Barca, Slovakia
  • Liptovsky Mikulas, Slovakia
10

References and documents

Publications

  • Newcomer JW, Eriksson H, Zhang P, Meehan SR, Weiss C. Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies. J Clin Psychiatry. 2019 Oct 1;80(6):18m12680. doi: 10.4088/JCP.18m12680. PubMed 31577867 ↗
  • Hobart M, Zhang P, Weiss C, Meehan SR, Eriksson H. Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale. Int J Neuropsychopharmacol. 2019 Mar 1;22(3):173-179. doi: 10.1093/ijnp/pyy095. PubMed 30508090 ↗
  • Hobart M, Skuban A, Zhang P, Augustine C, Brewer C, Hefting N, Sanchez R, McQuade RD. A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder. J Clin Psychiatry. 2018 May 22;79(4):17m12058. doi: 10.4088/JCP.17m12058. PubMed 29873953 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Apr 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2014
First posted
Jul 22, 2014
Start
Jul 2014
Primary completionActual
Apr 2016
CompletionActual
May 2016
Results first posted
Aug 21, 2018
Last update
Aug 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02196506
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jul 22, 2014
Start date
Jul 2014
Primary completion
Apr 2016
Completion
May 2016
Results posted
Aug 21, 2018
Last update
Aug 21, 2018

Study contacts

Claudette Brewer
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brexpiprazole · Antiandrogens

Start the discussion